Drug Profile
Allogeneic pancreatic cancer vaccine - CPL Biologicals
Alternative Names: DO-013Latest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Novavax
- Developer Cadila Pharmaceuticals; CPL Biologicals
- Class Cancer vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Pancreatic cancer